FOLH1 and prostate carcinoma: Aim: scFvD2B is a single chain variable fragment (29 kDa) of the monoclonal antibody IgGD2B specific to the extracellular domain of prostate specific membrane antigen (PSMA) overexpressed in prostate cancer (PCa).1,2 scFvD2B has shown promising properties, in terms of high stability, favorable pharmacokinetics and specificity, efficiently accumulating in PSMA-expressing PCa tumors.